# Contents

**Preface**  
XI

1  **General Aspects**  3  
1.1  History  5  
1.1.1  Willow Bark and Leaves as Antipyretic, Anti-Inflammatory Analgesics  5  
1.1.2  Salicylates as the Active Ingredient of Willow Bark and Other Natural Sources  6  
1.1.3  Synthesis of Acetylsalicylic Acid and First Clinical Studies  7  
1.1.4  Mode of Aspirin Action  12  
1.1.5  Anti-Inflammatory/Analgesic Actions of Aspirin  14  
1.1.6  Aspirin in the Cardiovascular System  15  
1.1.7  Current Research Topics  17  
1.2  Chemistry  25  
1.2.1  Structures and Chemical Properties of Salicylates  25  
1.2.1.1  Salicylates in Clinical Use  25  
1.2.1.2  Aspirin Formulations  27  
1.2.2  Determination of Salicylates  30  
1.2.2.1  Gas–Liquid Chromatography  30  
1.2.2.2  High-Performance Liquid Chromatography  30  
1.2.2.3  Spectrophotometry  30  

2  **Pharmacology**  33  
2.1  Pharmacokinetics  35  
2.1.1  Absorption and Distribution  36  
2.1.1.1  Absorption  36  
2.1.1.2  Particular Aspirin Formulations  40  
2.1.1.3  Distribution  40  
2.1.1.4  Modifying Factors  42  
2.1.2  Biotransformation and Excretion  46  
2.1.2.1  Biotransformation of Aspirin  46  
2.1.2.2  Biotransformations of Salicylic Acid  48  
2.1.2.3  Excretion of Salicylates  49
2.1.2.4 Modification of Biotransformations and Excretion of Salicylates 50
2.2 Cellular Modes of Action 53
2.2.1 Inhibition of Cyclooxygenases 54
2.2.1.1 Acetylation of Cyclooxygenases and Traditional NSAIDs 55
2.2.1.2 Modulation of COX-2 Gene Expression 61
2.2.1.3 Further Actions of Salicylates on Arachidonate Metabolism 62
2.2.2 COX-Independent Actions on Cell Function 66
2.2.2.1 Kinases 67
2.2.2.2 Transcription Factors 69
2.2.2.3 Oxidative Stress and Nitric Oxide 73
2.2.2.4 Immune Responses 75
2.2.3 Energy Metabolism 79
2.2.3.1 Fatty Acid β-Oxidation 80
2.2.3.2 Uncoupling of Oxidative Phosphorylation 82
2.2.3.3 Toxic Actions of Salicylates on the Liver 84
2.3 Actions on Organs and Tissues 88
2.3.1 Hemostasis and Thrombosis 89
2.3.1.1 Platelets 90
2.3.1.2 Endothelial Cells 95
2.3.1.3 Plasmatic Coagulation 98
2.3.1.4 Fibrinolysis 98
2.3.2 Inflammation, Pain, and Fever 105
2.3.2.1 Inflammation 106
2.3.2.2 Pain 110
2.3.2.3 Fever 113
2.3.3 Aspirin and Malignancies 120
2.3.3.1 COX-Related Antitumor Effects of Aspirin 120
2.3.3.2 Nonprostaglandin-Related Antitumor Actions of Aspirin 122
2.3.3.3 Nonspecific Actions of Salicylates 124

3 Toxicity and Drug Safety 129
3.1 Systemic Side Effects 131
3.1.1 Acute and Chronic Toxicity 132
3.1.1.1 Occurrence and Symptoms 132
3.1.1.2 Treatment 136
3.1.1.3 Habituation 139
3.1.2 Bleeding Disorders 142
3.1.2.1 Prolongation of Bleeding Time by Aspirin 142
3.1.2.2 Aspirin-Related Bleeding Risk in Surgical Interventions 144
3.1.2.3 Aspirin, Other Drugs, and Alcohol 146
3.1.2.4 Prevention and Treatment of Bleedings 146
3.1.3 Safety Pharmacology in Particular Life Situations 150
3.1.3.1 Pregnancy and Fetal Development 150
3.1.3.2 The Elderly Patient 153
3.2 Organ Toxicity 157
4.1.1.9 Actual Situation 250
4.1.2 Cerebrovascular Diseases 260
4.1.2.1 Thrombotic Risk and Mode of Aspirin Action 261
4.1.2.2 Clinical Trials: Primary Prevention 263
4.1.2.3 Clinical Trials: Secondary Prevention 265
4.1.2.4 Aspirin and Other Drugs 267
4.1.2.5 Actual Situation 270
4.1.3 Peripheral Arterial Disease 276
4.1.3.1 Thrombotic Risk and Mode of Aspirin Action 276
4.1.3.2 Clinical Trials: Primary Prevention 278
4.1.3.3 Clinical Trials: Secondary Prevention 279
4.1.3.4 Clinical Trials: Peripheral Transluminal Angioplasty (PTA) 281
4.1.3.5 Aspirin and Other Drugs 282
4.1.3.6 Actual Situation 283
4.1.4 Venous Thrombosis 287
4.1.4.1 Thrombotic Risk and Mode of Aspirin Action 287
4.1.4.2 Clinical Trials 287
4.1.4.3 Actual Situation 288
4.1.5 Preeclampsia 290
4.1.5.1 Thrombotic Risk and Mode of Aspirin Action 290
4.1.5.2 Clinical Trials 293
4.1.5.3 Clinical Trials in Pregnancy-Induced Hypertension: Reasons for Data Variability 294
4.1.5.4 Actual Situation 298
4.1.6 Aspirin “Resistance” 303
4.1.6.1 Definition and Types of Pharmacological Aspirin “Resistance” 304
4.1.6.2 Detection of Aspirin “Resistance” 304
4.1.6.3 Pharmacological Mechanisms of Aspirin “Resistance” 307
4.1.6.4 Clinical Trials 310
4.2 Pain, Fever, and Inflammatory Diseases 322
4.2.1 Aspirin as an Antipyretic Analgesic 322
4.2.1.1 Fever, Pain, and Antipyretic/Analgesic Actions of Aspirin 323
4.2.1.2 Clinical Trials 326
4.2.1.3 Aspirin and Other Drugs 327
4.2.1.4 Actual Situation 328
4.2.2 Arthritis and Rheumatism 332
4.2.2.1 Pathophysiology and Mode of Aspirin Action 332
4.2.2.2 Clinical Trials 334
4.2.2.3 Aspirin and Other Drugs 335
4.2.2.4 Actual Situation 336
4.2.3 Kawasaki Disease 339
4.2.3.1 Pathophysiology and Mode of Aspirin Action 339
4.2.3.2 Clinical Trials 340
4.2.3.3 Aspirin and Other Drugs 341
4.2.3.4 Actual Situation 341
4.3 Further Clinical Indications 343